category guide

How to Choose Imaging AI (Radiology SaMD)

May 2, 2026· 11 min read· AI-generated

How to Choose Imaging AI (Radiology SaMD)

What hospital radiology departments, imaging centers, and ASCs need to know before signing an AI contract — from FDA clearance specifics to five-year cost models.

What this is and who buys it

Imaging AI is the broad label for FDA-regulated software that applies machine learning and deep learning algorithms to radiological images — CT, MRI, X-ray, mammography, ultrasound, and dental radiographs — in order to triage, detect, or characterize findings. Regulators classify these tools as Software as a Medical Device (SaMD), a designation that carries specific premarket and post-market obligations distinct from hardware medical devices. The three functional categories you'll encounter most often are computer-aided triage (CADt), which re-orders worklists based on clinical urgency; computer-aided detection (CADe), which flags candidate lesions for radiologist review; and computer-aided diagnosis (CADx), which characterizes findings with a probability score or classification. These distinctions matter for procurement because each maps to different FDA product codes and reimbursement pathways.

The primary buyers are hospital radiology departments managing high-throughput CT or MRI volumes, independent diagnostic imaging centers looking to extend radiologist capacity, ambulatory surgery centers with onsite imaging, and dental group practices adopting AI-assisted radiograph review. Purchase decisions tend to cluster around three triggers: radiologist workforce constraints that create turnaround-time pressure, a PACS or RIS refresh that opens an integration window, or accreditation requirements pushing toward structured reporting and clinical decision support. The market has grown rapidly — the FDA had authorized 1,451 AI-enabled medical devices through end-2025, with 1,104 (76%) in radiology and 255 new radiology clearances granted in 2025 alone [S1].

What makes this category genuinely complex for procurement teams is that "imaging AI" spans everything from a single-algorithm stroke triage tool to a multi-modality platform running 20 concurrent algorithms across an enterprise scanner fleet. The technology, the regulatory footprint, and the financial model differ substantially across that range, and the evidence base for real-world clinical generalizability remains thinner than vendor marketing typically acknowledges [S2].

Key decision factors

FDA clearance specificity is the first thing to nail down, and it requires more precision than most buyers anticipate. Clearance numbers are modality- and indication-specific: a 510(k) covering noncontrast chest CT triage does not automatically cover chest X-ray triage, and a tool cleared for 1.5T MRI may not have been validated on 3T hardware. Relevant product codes to know are POK (CADx for cancer, 21 CFR §892.2060), MYN (medical image analyzers, 21 CFR §892.2070), QAS/QFM (CADt and notification, 21 CFR §892.2080), and QIH, the dominant post-2021 code covering AI-based imaging processing broadly. Verify the exact cleared indication against your intended clinical workflow — not the vendor's marketing summary.

Validation data generalizability determines whether a tool that performed well in a vendor's study will perform similarly in your department. The ECLAIR framework (European Radiology, 2021) requires that vendors disclose the demographics, scanner vendors, field strengths, contrast protocols, and acquisition parameters of both training and validation cohorts — and that the test set be fully disjoint from training data [S3]. An algorithm trained at a single academic center with a predominantly homogeneous patient population may show meaningful performance degradation when deployed on a community hospital scanner with a different demographic mix. A 2025 systematic review in JAMA Network Open confirmed that demographic mismatch is a documented source of algorithmic bias in FDA-cleared radiology AI [S2].

Integration architecture has a direct line to total cost. DICOM PS 3.x conformance and HL7 FHIR compatibility with your existing PACS, RIS, and EHR are non-negotiable requirements. Integrations that require proprietary middleware — a dedicated viewer, a vendor-specific broker, or a hardcoded API bridge — add roughly 20–30% to implementation costs and create long-term dependency on a single vendor's development roadmap.

Deployment model shapes both upfront capital and ongoing operating expense. Cloud SaaS eliminates the need for on-premises GPU inference servers (NVIDIA DGX-class nodes run approximately $40,000–$43,000 per unit), can go live in two to four weeks for single-modality tools, and converts capital to operating expense. The tradeoff is recurring per-scan or monthly fees — complex cloud AI platforms can run $5,000–$15,000 per month — plus a mandatory Business Associate Agreement with the vendor governing PHI. On-premises deployment suits facilities with strict data residency requirements or latency constraints, but it demands IT infrastructure investment and a longer integration timeline (60–90 days for enterprise-scale testing).

The Predetermined Change Control Plan (PCCP) is a newer regulatory concept that has direct operational implications. Under FDA's January 2025 draft guidance on AI lifecycle management, vendors that file a PCCP commit to a defined scope within which algorithm updates can be made without a new 510(k) submission. If a vendor has no PCCP, every performance-altering model update triggers a new regulatory submission — meaning your deployed algorithm could lag behind the vendor's current version for months while a new clearance is processed. This is a material operational risk for tools in fast-moving areas like oncology screening.

Reimbursement pathway is frequently overstated in vendor conversations. Only a narrow set of imaging AI tools have secured separate CMS payment — a handful of tools have obtained NTAP (New Technology Add-on Payment) under IPPS or coverage under OPPS APCs. The vast majority of cleared AI tools are bundled into existing imaging DRGs and generate no independent billing. A fixed-cost licensing model has been shown in a 2025 systematic review in Radiology: Artificial Intelligence to outperform per-scan pricing for cost-effectiveness in high-volume settings, because per-scan costs scale with utilization in ways that are difficult to forecast.

AI artifact risk belongs in every procurement checklist for reconstruction tools. ECRI flagged AI-based image reconstruction artifacts as a Top 10 Health Technology Hazard in 2024, noting that deep-learning reconstruction on CT and MRI can both obscure genuine findings and create synthetic features that mimic pathology. For any DL reconstruction tool, require the vendor's artifact characterization testing documentation and specify contractual acceptance criteria before go-live sign-off.

What it costs

Pricing in this market is highly variable and not uniformly publicly disclosed. Per-scan SaaS fees, flat monthly subscriptions, enterprise platform licenses, and one-time perpetual licenses all coexist, and vendors rarely publish list prices. The ranges below reflect the advisory's modeled bands — treat them as planning figures, not quotes.

Entry tier ($15,000–$60,000/year): Single-algorithm CADt or CADe tools, typically cloud-based, aimed at smaller imaging centers or single-modality workflows.
Mid tier ($60,000–$300,000/year): Multi-algorithm platforms or enterprise single-algorithm deployments; includes integration and support services.
Premium tier ($300,000+/year or one-time): Enterprise multi-site, multi-modality platforms; on-premises GPU infrastructure; bespoke integration and model customization agreements.

A 2024 JACR ROI model (Bayer-funded) estimated a multi-algorithm radiology AI platform at approximately $1.78M total cost over five years against roughly $3.56M in estimated revenues and labor savings — but the authors acknowledged high context-dependence, and independent replication is limited.

Common use cases

Imaging AI has a practical foothold in four clinical workflows where the combination of high case volume, time pressure, and clear performance endpoints makes the ROI case most legible.

Emergency triage (CADt): Auto-escalation of worklist priority for intracranial hemorrhage, large-vessel occlusion, pulmonary embolism, or obstructive hydrocephalus on noncontrast CT. Published sensitivity for select cleared tools exceeds 95%.
Oncology screening (CADe/CADx): Lung nodule detection on chest CT, mammography AI, and bi-parametric prostate MRI analysis; these fall under product code POK (21 CFR §892.2060).
Quantitative neuroimaging: Brain volume measurement, white matter hyperintensity segmentation, and atrophy staging for neurodegenerative workup — several tools reached 510(k) clearance in 2025.
Dental radiograph analysis: AI-assisted detection of caries, bone loss, and periapical pathology on panoramic and bitewing films; validated cleared tools exist with published MRMC data.

Regulatory and compliance

Approximately 97% of FDA-authorized AI-enabled medical devices are cleared as Class II through the 510(k) premarket notification pathway under the substantial equivalence standard [S1]. Only four AI-enabled devices have required Class III Premarket Approval (PMA), and 22 went through De Novo classification. SaMD vendors are also required to comply with IEC 62304 (medical device software lifecycle processes) and IEC 82304-1 (general requirements for health software). For interoperability, confirm the vendor's DICOM Conformance Statement against the specific SOP classes your PACS requires — generic "DICOM-compatible" claims are insufficient for enterprise procurement.

On the data governance side, any patient imaging data processed by a cloud-based AI system constitutes PHI under 45 CFR Parts 160 and 164. A signed Business Associate Agreement with the vendor is mandatory before any live data flows to their infrastructure — this is a legal requirement, not a best practice. FDA's 2025 draft AI lifecycle guidance also reinforces post-market surveillance obligations: if the vendor's cleared algorithm version is materially updated, procurement contracts should include notification rights and the right to review updated validation data before the new version is deployed in your environment [S2].

Service, training, and total cost of ownership

Integration work is consistently underestimated. Budget 60–90 days for enterprise-scale DICOM/HL7 integration testing between the AI platform and your PACS, RIS, and EHR — and add 20–30% to initial deployment costs to account for middleware configuration, worklist routing rules, and interface testing. Cloud deployments on a single modality can compress that to two to four weeks, but multi-site, multi-modality deployments at the enterprise tier take longer regardless of deployment model.

Training is the largest hidden cost driver in failed AI adoptions. Role-specific onboarding — radiologists learning to interpret AI outputs critically, technologists understanding acquisition protocol requirements, IT managing model versioning — is consistently cited as the primary cause of delayed ROI. Designating a clinical AI champion within the radiology department, rather than treating this as a standard IT rollout, meaningfully improves adoption outcomes. Annual software maintenance contracts typically run 15–25% of initial licensing cost; budget separately for model retraining if your scanner fleet or patient population changes significantly, as AI models can show performance drift within two to three years of deployment even without a formal platform overhaul. SaMD platforms generally undergo major architecture overhauls on a five-to-seven-year cycle.

For SLAs, triage tools specifically should carry a contractual uptime guarantee of ≥99.5%, given that a down CADt system in an ED setting creates a patient safety gap, not merely a workflow inconvenience. Require explicit data portability provisions at contract end — the ability to export your deployment configuration and access historical performance data — to avoid being locked into a vendor relationship by operational inertia.

Red flags to watch for

A vendor presenting internal accuracy metrics without a published or disclosed MRMC study using a fully disjoint test set is offering unvalidated performance claims. Per ECLAIR guidelines, algorithms evaluated on the same data used for development cannot be assumed to generalize [S3].

If the training cohort demographics — age distribution, ethnicity, scanner manufacturer, field strength, contrast protocol — are not disclosed or don't approximate your patient population, you are buying algorithmic risk. A 2025 JAMA Network Open systematic review documented this as a confirmed source of performance degradation in deployed FDA-cleared tools [S2].

Be cautious of broad reimbursement claims. A vendor implying that their tool generates independent CMS billing should be able to point to a specific APC code or NTAP approval decision — very few tools can do this.

Finally, watch for proprietary PACS lock-in. If integration requires a dedicated viewer or vendor-specific middleware that prevents other AI algorithms from running on the same dataset, you are paying integration overhead again for every additional tool you evaluate in the future.

Questions to ask vendors

Provide the exact FDA 510(k) number, product code, and cleared indication — does it cover our specific imaging modality (e.g., 1.5T vs. 3T MRI, specific CT detector count) and patient population?
Share the full validation dataset disclosure: number of cases, scanner vendors, field strengths, acquisition protocols, patient demographics, and confirmation that the test set was fully disjoint from training data (TRIPOD/ECLAIR compliant)?
Has a Predetermined Change Control Plan (PCCP) been filed with FDA — and what algorithm changes are covered versus which would require a new 510(k)?
What DICOM SOP classes and HL7 FHIR resource types are in your conformance statement, and have you integrated with our specific PACS and RIS versions in a live production environment?
What is the five-year total cost of ownership broken down by license fees, per-scan charges, integration services, model retraining, and support — and is a fixed-cost alternative to per-scan pricing available?
How do you detect algorithmic drift in post-market use, and what is the contractual remedy if real-world sensitivity or specificity falls below the cleared performance threshold?

Alternatives

The choice between a standalone algorithm and a multi-algorithm platform is the first structural decision. A single-use CADt tool — stroke triage only, for example — carries a narrower validation scope, lower initial cost, and faster deployment, but each additional algorithm from a different vendor replicates integration overhead. Multi-algorithm platforms spread that cost across tools and simplify governance; ECRI's 2024 Top 10 Hazards report identified "insufficient AI governance" as a top risk when multiple point solutions from different vendors coexist without centralized performance monitoring.

Cloud SaaS vs. on-premises: Cloud removes GPU hardware costs and deploys faster, but subscription fees accumulate and PHI governance requires a BAA. On-premises suits high-volume environments with data residency requirements.
Scanner-embedded OEM AI vs. third-party SaaS: Embedded AI (e.g., deep-learning reconstruction tools integrated directly into scanner software) is tightly validated for that hardware platform and eliminates PACS integration effort, but constrains future scanner vendor optionality. Vendor-neutral orchestration platforms allow algorithm portability across scanner fleets.
Fixed license vs. per-scan pricing: Fixed-cost models have demonstrated better cost-effectiveness at high volume in a 2025 systematic review; per-scan pricing becomes difficult to forecast as imaging volumes fluctuate.
Pilot before full deployment: Given the generalizability gaps documented in the literature [S2], a 90-day prospective pilot with pre-agreed performance acceptance criteria — sensitivity, specificity, false-positive rate per 1,000 scans — before committing to a multi-year enterprise contract is strongly advisable.

Sources

Browse vendors in

Imaging AI

MedSource publishes neutral guidance. We do not accept payment from vendors to influence the content of articles. AI-generated articles are reviewed for factual accuracy but cited sources should be the primary reference for procurement decisions.